| 摘要 |
The invention relates to a multi-targeted method for triple-negative breast cancer therapy which identifies alternative ways to induce apoptosis and to develop a new therapeutical strategy for inhibiting proliferation of breast tumour cells. According to the invention, the method consists in combining the chemotherapeutic effect of EGCG with the targeted therapy with TNF- α and RNA by identifying signalling ways able to interfere with the apoptosis regulating mechanisms by administering a single dose of 50 nM TNF- α and RNA, in parallel with administering a dose of 10 μ M EGCG, using as a transfection agent PORT NeoFX on the cell line Hs578T, as tumour cell death inducing and supporting agent, the two agents acting upon multiple genes involved in apoptosis modulation by activation of a high number of genes with pro-apoptosis role and inhibition of the expression level of anti-apoptosis genes with direct implications in cancer therapy. |
